Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NSC-118,994

Known as: NSC-118994 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1981
Review
1981
All Phase II studies with diglycoaldehyde with leukemia and solid tumors have been reviewed. The dose schedules employed ranged… Expand
1978
1978
The effects of the anticancer drug diglycolaldehyde (NSC-118994) were studied on Chinese hamster ovary cells growing in vitro… Expand
1977
1977
Abstract Inox (NSC-118994) was studied with the use of the 14 C-labeled compound to further delineate its intracellular… Expand
1976
1976
: Inosine dialdehyde (IdA), a new antitumor agent presently undergoing clinical evaluation in man, possesses two aldehyde groups… Expand
1976
1976
Inosine dialdehyde (IdA), a new antitumor agent presently undergoing clinical evaluation in man, possesses two aldehyde groups… Expand
1976
1976
The pharmacologic disposition of inosine dialdehyde (IdA) was studied in mice, rats, dogs, and monkeys. 14C-IdA was utilized to… Expand
1976
1976
: The pharmacologic disposition of inosine dialdehyde (IdA) was studied in mice, rats, dogs, and monkeys. 14C-IdA was utilized to… Expand
1975
1975
An initial clinical phase I trial of inosine dialdehyde has been carried out in 40 patients at dose levels of 30-4000 mg/m2 for 5… Expand
1975
1975
  • R. Cysyk
  • Cancer chemotherapy reports
  • 1975
  • Corpus ID: 38585519
Inosine dialdehyde, an antitumor agent highly active against several murine tumors, ispresently undergoing clinical trial for… Expand